The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The FDA aims to make a decision by April 8, 2026
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The companies aim to expand treatment options for millions living with metabolic disorders
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The company had achieved the highest "A" rating in Climate Change
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The product will be marketed by Dr. Reddy's Laboratories Inc.
The company will respond to the US FDA within the stipulated timelines
Subscribe To Our Newsletter & Stay Updated
